NAD+ (Blood/Tissue Levels)

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme essential for cellular energy metabolism and DNA repair, and its blood or tissue concentration is claimed to decline with age, driving interest in NAD-boosting supplements like NR and NMN. The core claim: restoring NAD+ levels through supplementation can reverse aspects of cellular aging by supporting sirtuin activity, DNA repair enzymes (PARPs), and mitochondrial function [2].

Evidence for age-related NAD+ decline is substantial in animal models but more mixed and tissue-dependent in humans. A comprehensive review found NAD+ decline of roughly 15-65% in aged rodent skeletal muscle and 10-50% in aged rodent liver across different studies, while human data show declines of at least 50% in skin samples across adult aging and around 14% in cerebrospinal fluid in people over 45 compared to those 45 and younger [1]. Two MRI-based brain studies found 10-25% declines with age, but a third preprint study found no consistent difference between young and old human brains, and blood NAD+ measurement remains technically inconsistent across labs and studies, complicating direct comparison [1].

How to measure it: blood NAD+ is measured via mass spectrometry or enzymatic cycling assays on whole blood or peripheral blood mononuclear cells, since plasma NAD+ concentrations are very low and technically difficult to measure reliably [3]. Results vary substantially by assay method and sample handling, and there is no broadly standardized clinical reference range [4].

How to intervene on it: nicotinamide riboside (NR) supplementation has been shown in randomized controlled trials to reliably raise the NAD+ metabolome in blood; a placebo-controlled trial found NR supplementation increased blood NAD+ levels in a dose-dependent manner with good tolerability. Nicotinamide mononucleotide (NMN) shows similar blood NAD+-raising effects in smaller human trials [5]. However, raising blood NAD+ levels has not yet been conclusively linked in large human RCTs to functional outcomes like grip strength, VO2max, or mortality, the biomarker moves, but downstream clinical benefit remains unproven at scale.

Critics note that blood or even tissue NAD+ concentration may not reflect the flux, or turnover rate, that actually matters for cellular energy metabolism, and that measurement inconsistency across studies makes cross-study comparison difficult [4]. Some researchers also point out that supplementing NAD+ precursors could theoretically feed cancer cell metabolism, since rapidly dividing cells also depend heavily on NAD+-dependent pathways, though this concern remains theoretical without direct human trial evidence of increased cancer risk [3].

Bryan Johnson's Blueprint protocol tracks NAD+ blood levels as one panel biomarker while supplementing NAD precursors, an n=1 self-report [6].

The plain takeaway: NAD+ does appear to decline with age in multiple tissues, though the degree varies by tissue and study, and NR/NMN supplements reliably raise blood NAD+ levels, but no large human trial has yet shown that boosting NAD+ translates into meaningfully better function, disease prevention, or extended lifespan.